Sp103

CURRENT ROLE OF NONBIOLOGIC TREATMENT OPTIONS IN EOE

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed. This session will examine all treatment options, review the importance of treat to target in EoE and examine if the endpoint of the disease, fibrosis can be reversed now or in the future. LIVE STREAM SESSION

Presenter

Speaker Image for Nirmala Gonsalves
Northwestern University - The Feinberg School of Medicine

Tracks

Related Products

Thumbnail for LONGITUDINAL EFFECTS OF TREATMENT ON ESOPHAGEAL DYSMOTILITY IN EOSINOPHILIC ESOPHAGITIS
LONGITUDINAL EFFECTS OF TREATMENT ON ESOPHAGEAL DYSMOTILITY IN EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Thumbnail for EOSINOPHILIC ESOPHAGITIS
EOSINOPHILIC ESOPHAGITIS
This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field…
Thumbnail for <i>THE SEVERITY OF REDUCED ESOPHAGEAL DISTENSIBILITY PARALLELS EOSINOPHILIC DISEASE DURATION</i>
<i>THE SEVERITY OF REDUCED ESOPHAGEAL DISTENSIBILITY PARALLELS EOSINOPHILIC DISEASE DURATION</i>
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy…